- Aimovig ® is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.Twitter Linkedin Facebook Pinterest Google plus
Indication
The EMA label of Aimovig ® states approval for patients with at least 4 monthly migraine days.
Although the reimbursement criteria in Belgium are more limited, Aimovig ® is indicated for patients with at least 8 monthly...
Twitter Linkedin Facebook Pinterest Google plusReimbursement
Aimovig ® reimbursement criteria in Belgium and LuxembourgIn Luxembourg , Aimovig ® (70mg and 140mg) is reimbursed at 80% in line with the EU label (for...
Twitter Linkedin Facebook Pinterest Google plusDosing
Administration supportAimovig ® is available as an auto-injector pen with 2 dosages, 70mg and 140mg and is self-administered every 4 weeks. Below you find an administration support video in ENG, FR and NL that provides a...
Twitter Linkedin Facebook Pinterest Google plusSafety Profile
SAFETY AND TOLERABILITY PROFILE _
ü No additional monitoring needed 1 . ü Based on clinical trial experience in > 3.000 patients, the overall incidence of adverse events with Aimovig ® was comparable to placebo ...Twitter Linkedin Facebook Pinterest Google plusMechanism of Action
References: 1. Aimovig® Core Data Sheet v2.3. 2. Shi L, et al. J Pharmacol Exp Ther 2016; 356: 223-231. 3. Foltz IN, et al. Circulation 2013; 127(22): 2222-30. 4. Levin M, et al. Headache 2018; 58 (10): 1689-1696...
Twitter Linkedin Facebook Pinterest Google plusEfficacy
Aimovig ® has demonstrated benefit across the migraine spectrumReferences
Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med,...Twitter Linkedin Facebook Pinterest Google plus